Log in

Relevant bibliographies by topics / Multiple endpoints / Journal articles

To see the other types of publications on this topic, follow the link: Multiple endpoints.

Journal articles on the topic 'Multiple endpoints'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Multiple endpoints.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Chi, George Y. H. "Multiple Testings: Multiple Comparisons and Multiple Endpoints." Drug Information Journal 32, no. 1_suppl (1998): 1347S—1362S. http://dx.doi.org/10.1177/00928615980320s131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dueck, Amylou, Paul J. Novotny, and Jeff A. Sloan. "Dealing with Multiple Endpoints." Current Problems in Cancer 30, no. 6 (2006): 298–306. http://dx.doi.org/10.1016/j.currproblcancer.2006.08.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Häberle, Lothar, Annette Pfahlberg, and Olaf Gefeller. "Assessment of Multiple Ordinal Endpoints." Biometrical Journal 51, no. 1 (2009): 217–26. http://dx.doi.org/10.1002/bimj.200810502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hasler, Mario, and Kathrin Böhlendorf. "Multiple Comparisons for Multiple Endpoints in Agricultural Experiments." Journal of Agricultural, Biological, and Environmental Statistics 18, no. 4 (2013): 578–93. http://dx.doi.org/10.1007/s13253-013-0149-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Tsai, Kao-Tai, and James A. Kozial. "Assessing multiple endpoints with ordered alternatives." Communications in Statistics - Theory and Methods 23, no. 2 (1994): 533–44. http://dx.doi.org/10.1080/03610929408831270.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Xu, Jane, and Scott L. Zeger. "The Evaluation of Multiple Surrogate Endpoints." Biometrics 57, no. 1 (2001): 81–87. http://dx.doi.org/10.1111/j.0006-341x.2001.00081.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Eaton, Morris L., and Robb J. Muirhead. "On a multiple endpoints testing problem." Journal of Statistical Planning and Inference 137, no. 11 (2007): 3416–29. http://dx.doi.org/10.1016/j.jspi.2007.03.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Quan, Hui, Jim Bolognese, and Weiying Yuan. "Assessment of equivalence on multiple endpoints." Statistics in Medicine 20, no. 21 (2001): 3159–73. http://dx.doi.org/10.1002/sim.985.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ishihara, Takuma, and Kouji Yamamoto. "A Test for Multiple Binary Endpoints with Continuous Latent Distribution in Clinical Trials." Journal of Statistical Theory and Applications 20, no. 4 (2021): 463–80. http://dx.doi.org/10.1007/s44199-021-00003-3.

Full text

Abstract:

AbstractIn clinical trials, two or more binary responses obtained by dichotomizing continuous responses are often employed as multiple primary endpoints. Testing procedures for multiple binary variables with latent distribution have not yet been adequately discussed. Based on the association measure among latent variables, we provide a statistic for testing the superiority of at least one binary endpoint. In addition, we propose a testing procedure with a framework in which the trial efficacy is confirmed only when there is superiority of at least one endpoint and non-inferiority of the remain

APA, Harvard, Vancouver, ISO, and other styles

10

Wei, Xinmiao, Tengxin Huang, Zhijiang Yang, Li Pan, Liangliang Wang, and Junjie Ding. "Quantitative Predictive Studies of Multiple Biological Activities of TRPV1 Modulators." Molecules 29, no. 2 (2024): 295. http://dx.doi.org/10.3390/molecules29020295.

Full text

Abstract:

TRPV1 channel agonists and antagonists, which have powerful analgesic effects without the addictive qualities associated with traditional analgesics, have become a focus area for the development of novel analgesics. In this study, quantitative structure–activity relationship (QSAR) models for three bioactive endpoints (Ki, IC50, and EC50) were successfully constructed using four machine learning algorithms: SVM, Bagging, GBDT, and XGBoost. These models were based on 2922 TRPV1 modulators and incorporated four types of molecular descriptors: Daylight, E-state, ECFP4, and MACCS. After the rigoro

APA, Harvard, Vancouver, ISO, and other styles

11

Candida Fratazzi and Jixiao Niu. "Accelerated orphan drug approval: surrogate endpoints." World Journal of Advanced Pharmaceutical and Medical Research 2, no. 1 (2022): 001–7. http://dx.doi.org/10.53346/wjapmr.2022.2.1.0021.

Full text

Abstract:

Today, orphan drug development is confronted with significant challenges represented by the considerable complexity, diversity of clinical manifestations, and competition in study recruitment. Thus, surrogate endpoints adoption plays a crucial role in rare disease trials by minimizing costs, the number of subjects, and study duration. Surrogate endpoints, to substitute for a direct measure of how patients feel, function, or survive, must be biomarkers that directly correlate with disease clinical manifestations and predict the impact of study drug on the long-term disease progression. Validati

APA, Harvard, Vancouver, ISO, and other styles

12

Jin, Man, and Pingye Zhang. "An adaptive seamless Phase 2-3 design with multiple endpoints." Statistical Methods in Medical Research 30, no. 4 (2021): 1143–51. http://dx.doi.org/10.1177/0962280220986935.

Full text

Abstract:

Adaptive seamless Phase 2-3 design has been considered as one possible way to expedite development time for a drug program by allowing the expansion from an ongoing Phase 2 trial into a Phase 3 trial. Multiple endpoints are often tested when a regulatory approval is pursued. Here we propose an adaptive seamless Phase 2-3 design with multiple endpoints which can expand an ongoing Phase 2 trial into a Phase 3 trial based on an intermediate endpoint for adaptive decision and test the endpoints with a powerful multiple test procedure. It is proved that the proposed design can preserve the familywi

APA, Harvard, Vancouver, ISO, and other styles

13

Santosh Kumar, Rada, and A. Rama Krishna. "Clinical Endpoint: Substitute for Prediction of Clinical Benefit." Journal of Drug Delivery and Therapeutics 9, no. 4-s (2019): 800–802. http://dx.doi.org/10.22270/jddt.v9i4-s.3367.

Full text

Abstract:

An endpoint is a primary or secondary outcome used to judge the effectiveness of a treatment; it is a precisely defined variable intended to reflect an outcome of interest thatis statistically analyzed. An endpoint usually specifies the sort of assessments made, the timing of those assessments, the assessment tools used and possibly other details, as applicable, such as how multiple assessments within an individual are to be combined. There are different types of endpoints used in clinical trails like primary endpoint, secondary endpoint, multiple endpoint and surrogate endpoint. Primary endpo

APA, Harvard, Vancouver, ISO, and other styles

14

Baracaldo-Santamaría, Daniela, John Edwin Feliciano-Alfonso, Raul Ramirez-Grueso, Luis Carlos Rojas-Rodríguez, Camilo Alberto Dominguez-Dominguez, and Carlos Alberto Calderon-Ospina. "Making Sense of Composite Endpoints in Clinical Research." Journal of Clinical Medicine 12, no. 13 (2023): 4371. http://dx.doi.org/10.3390/jcm12134371.

Full text

Abstract:

Multiple drugs currently used in clinical practice have been approved by regulatory agencies based on studies that utilize composite endpoints. Composite endpoints are appealing because they reduce sample size requirements, follow-up periods, and costs. However, interpreting composite endpoints can be challenging, and their misuse is not uncommon. Incorrect interpretation of composite outcomes can lead to misleading conclusions that impact patient care. To correctly interpret composite outcomes, several important questions should be considered. Are the individual components of the composite ou

APA, Harvard, Vancouver, ISO, and other styles

15

Kavia, RBC, D. De Ridder, CS Constantinescu, CG Stott, and CJ Fowler. "Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis." Multiple Sclerosis Journal 16, no. 11 (2010): 1349–59. http://dx.doi.org/10.1177/1352458510378020.

Full text

Abstract:

Background: Bladder dysfunction is a common feature of multiple sclerosis (MS). Objective: In this study we aimed to assess the efficacy, tolerability and safety of Sativex® (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS. Methods: We undertook a 10-week, double-blind, randomized, placebo-controlled, parallel-group trial in 135 randomized subjects with MS and overactive bladder (OAB). Results: The primary endpoint was the reduction in daily number of urinary incontinence episodes from baseline to end of treatment (8 weeks). Other endpoints included inciden

APA, Harvard, Vancouver, ISO, and other styles

16

Chen, James J. "P-value adjustment for multiple binary endpoints." Communications in Statistics - Theory and Methods 27, no. 11 (1998): 2791–806. http://dx.doi.org/10.1080/03610929808832255.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Whitehouse, C. A., A. M. Bothwell, E. J. Tawn, and R. Wood. "Radiation Dose Estimation Using Multiple Cytogenetic Endpoints." Radiation Protection Dosimetry 72, no. 2 (1997): 127–30. http://dx.doi.org/10.1093/oxfordjournals.rpd.a032082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ristl, Robin, Dong Xi, Ekkehard Glimm, and Martin Posch. "Optimal exact tests for multiple binary endpoints." Computational Statistics & Data Analysis 122 (June 2018): 1–17. http://dx.doi.org/10.1016/j.csda.2018.01.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Hasler, Mario, and Ludwig A. Hothorn. "A Dunnett-Type Procedure for Multiple Endpoints." International Journal of Biostatistics 7, no. 1 (2011): 1–15. http://dx.doi.org/10.2202/1557-4679.1258.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Montgomery, Robert N., and Jonathan D. Mahnken. "A prediction‐based test for multiple endpoints." Statistics in Medicine 39, no. 28 (2020): 4267–80. http://dx.doi.org/10.1002/sim.8724.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wang, Yueyue, Crystal Haskell-Ramsay, Jose Lara Gallegos, and John K. Lodge. "Inter-Individual Responses to a Blueberry Intervention across Multiple Endpoints." Nutrients 16, no. 6 (2024): 895. http://dx.doi.org/10.3390/nu16060895.

Full text

Abstract:

Inter-individual variation exists in response to diet and in the endpoints related to vascular diseases and cognitive impairment. Therefore, the evaluation and characterisation of responses to a dietary intervention targeting these endpoints is important. A dietary intervention with 37 participants has been performed comparing two forms of blueberry, either whole fresh blueberry (160 g), freeze-dried blueberry powder (20 g) or a placebo control (microcrystalline cellulose), in a 1-week single-blinded cross-over randomised controlled trial (RCT) in a healthy population. The response to the inte

APA, Harvard, Vancouver, ISO, and other styles

22

Ashall, Vanessa. "Endpoint Matrix: a conceptual tool to promote consideration of the multiple dimensions of humane endpoints." ALTEX 31, no. 2 (2014): 209–13. http://dx.doi.org/10.14573/altex.1307261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bar-Zohar, D., F. Agosta, D. Goldstaub, and M. Filippi. "Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives." Multiple Sclerosis Journal 14, no. 6 (2008): 719–27. http://dx.doi.org/10.1177/1352458507088102.

Full text

Abstract:

Magnetic resonance imaging (MRI) has revolutionized the diagnosis and management of patients with multiple sclerosis (MS). Conventional MRI metrics are employed as primary endpoints in proof-of-concept clinical trials evaluating new drugs for MS and as secondary endpoints in definitive phase III trials. Metrics derived from non-conventional MRI techniques are now emerging and hold significant promise since they appear to be more correlated with the most disabling features of MS. However, none of these has been approved for use as a surrogate endpoint for accumulation of physical disability, wh

APA, Harvard, Vancouver, ISO, and other styles

24

Lavery, Amy M., Leonard H. Verhey, and Amy T. Waldman. "Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials." Multiple Sclerosis International 2014 (2014): 1–13. http://dx.doi.org/10.1155/2014/262350.

Full text

Abstract:

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that manifests as acute relapses and progressive disability. As a primary endpoint for clinical trials in MS, disability is difficult to both characterize and measure. Furthermore, the recovery from relapses and the rate of disability vary considerably among patients. Given these challenges, investigators have developed and studied the performance of various outcome measures and surrogate endpoints in MS clinical trials. This review defines the outcome measures and surrogate endpoints used to date in MS clinical tr

APA, Harvard, Vancouver, ISO, and other styles

25

Kieser, M., and G. Rauch. "Multiplicity Adjustment for Composite Binary Endpoints." Methods of Information in Medicine 51, no. 04 (2012): 309–17. http://dx.doi.org/10.3414/me11-01-0044.

Full text

Abstract:

SummaryBackground: Binary composite outcome measures are increasingly used as primary endpoints in clinical trials. Composite endpoints combine several events of interest within a single variable. However, as the effect observed for the composite does not necessarily reflect the effects for the individual components, it is recommended in the literature to additionally evaluate each component separately.Objectives: The task is to define an adequate multiple test procedure which focuses on the composite outcome measure but allows for a confirmatory interpretation of the components in case of lar

APA, Harvard, Vancouver, ISO, and other styles

26

Rauch, Geraldine, and Meinhard Kieser. "Adaptive designs for clinical trials with multiple endpoints." Clinical Investigation 5, no. 5 (2015): 433–35. http://dx.doi.org/10.4155/cli.14.138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pocock, Stuart J., Nancy L. Geller, and Anastasios A. Tsiatis. "The Analysis of Multiple Endpoints in Clinical Trials." Biometrics 43, no. 3 (1987): 487. http://dx.doi.org/10.2307/2531989.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Mor, Maria K., and Stewart J. Anderson. "A Bayesian Group Sequential Approach for Multiple Endpoints." Sequential Analysis 24, no. 1 (2005): 45–62. http://dx.doi.org/10.1081/sqa-200046829.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Chang, Mark, and Shein-Chung Chow. "Analysis Strategies for Adaptive Designs with Multiple Endpoints." Journal of Biopharmaceutical Statistics 17, no. 6 (2007): 1189–200. http://dx.doi.org/10.1080/10543400701645348.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Van Der Schaaf, A., C. Schilstra, J. A. Langendijk, and A. van't Veld. "DATA-EFFICIENCY OF NTCP MODELLING USING MULTIPLE ENDPOINTS." Radiotherapy and Oncology 92 (August 2009): S240. http://dx.doi.org/10.1016/s0167-8140(12)73234-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kiyosawa, Naoki, Yosuke Ando, Kyoko Watanabe, Noriyo Niino, Sunao Manabe, and Takashi Yamoto. "Scoring multiple toxicological endpoints using a toxicogenomic database." Toxicology Letters 188, no. 2 (2009): 91–97. http://dx.doi.org/10.1016/j.toxlet.2009.03.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Walker, A. Sarah, and Abdel G. Babiker. "S36 Multiple endpoints en trials en HIV infection." Controlled Clinical Trials 18, no. 3 (1997): S63. http://dx.doi.org/10.1016/s0197-2456(97)91021-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Gönen, Mithat, Peter H. Westfall, and Wesley O. Johnson. "Bayesian Multiple Testing for Two-Sample Multivariate Endpoints." Biometrics 59, no. 1 (2003): 76–82. http://dx.doi.org/10.1111/1541-0420.00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Shi, Qian, Emily S. Pavey, and Rickey E. Carter. "Bonferroni-based correction factor for multiple, correlated endpoints." Pharmaceutical Statistics 11, no. 4 (2012): 300–309. http://dx.doi.org/10.1002/pst.1514.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Follmann, Dean. "Multivariate tests for multiple endpoints in clinical trials." Statistics in Medicine 14, no. 11 (1995): 1163–75. http://dx.doi.org/10.1002/sim.4780141103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Wang, Bushi, and Xinping Cui. "A new partition testing strategy for multiple endpoints." Statistics in Medicine 31, no. 20 (2012): 2151–68. http://dx.doi.org/10.1002/sim.5366.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Belaunzaran, Miguel, Shahm Raslan, Aleeza Ali, Kevin Newsome, Mark McKenney, and Adel Elkbuli. "Utilization and Efficacy of Resuscitation Endpoints in Trauma and Burn Patients: A Review Article." American Surgeon 88, no. 1 (2021): 10–19. http://dx.doi.org/10.1177/00031348211060424.

Full text

Abstract:

Shock is a sequelae in trauma and burn patients that substantially increases the risk for morbidity and mortality. The use of resuscitation endpoints allows for improved management of these patients, with the potential to prevent further morbidity/mortality. We conducted a review of the current literature on the efficacy of hemodynamic, metabolic, and regional resuscitation endpoints for use in trauma and burn patients. Hemodynamic endpoints included mean arterial pressure (MAP), heart rate (HR), urinary output (UO), compensatory reserve index (CRI), intrathoracic blood volume, and stroke volu

APA, Harvard, Vancouver, ISO, and other styles

38

Stoddard, Josh, Adam Mustafa, and Naveen Goela. "Tanium reveal." Proceedings of the VLDB Endowment 14, no. 12 (2021): 3096–109. http://dx.doi.org/10.14778/3476311.3476386.

Full text

Abstract:

Tanium Reveal is a federated search engine deployed on large-scale enterprise networks that is capable of executing data queries across billions of private data files within 60 seconds. Data resides at the edge of networks, potentially distributed on hundreds of thousands of endpoints. The anatomy of the search engine consists of local inverse indexes on each endpoint and a global communication platform called Tanium for issuing search queries to all endpoints. Reveal enables asynchronous parsing and indexing on endpoints without noticeable impact to the endpoints' primary functionality. The e

APA, Harvard, Vancouver, ISO, and other styles

39

Revankar, Sanjay G., William R. Kirkpatrick, Robert K. McAtee, et al. "Interpretation of Trailing Endpoints in Antifungal Susceptibility Testing by the National Committee for Clinical Laboratory Standards Method." Journal of Clinical Microbiology 36, no. 1 (1998): 153–56. http://dx.doi.org/10.1128/jcm.36.1.153-156.1998.

Full text

Abstract:

Trailing endpoints remain a problem in antifungal susceptibility testing using the National Committee for Clinical Laboratory Standards (NCCLS) method. For isolates for which trailing endpoints are found, MICs of ≤1 μg/ml at 24 h and of >64 μg/ml at 48 h are usually observed. In a study of human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis, we identified three patients with multiple serial isolates for which trailing endpoints were observed with fluconazole. At 24 h, MICs were generally ≤1 μg/ml by both broth macro- and microdilution methods. However, at 48

APA, Harvard, Vancouver, ISO, and other styles

40

Legault, Claudine. "68A Analyzing multiple endpoints from multiple time periods with multiple groups: The PEPI cohort." Controlled Clinical Trials 16, no. 3 (1995): 71S. http://dx.doi.org/10.1016/0197-2456(95)90479-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ashall, Vanessa. "Erratum to Endpoint Matrix: a Conceptual tool to Promote Consideration of the Multiple Dimensions of Humane Endpoints." ALTEX 31, no. 4 (2014): 422. http://dx.doi.org/10.14573/altex.1409081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Sun, Hengrui, Ellen Snyder, and Gary G. Koch. "Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints." Journal of Biopharmaceutical Statistics 28, no. 1 (2017): 189–211. http://dx.doi.org/10.1080/10543406.2017.1378664.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Elser, C., G. Pond, E. Chen, and L. Siu. "A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens." Journal of Clinical Oncology 25, no. 18_suppl (2007): 6569. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6569.

Full text

Abstract:

6569 Background: New phase II trial designs have been proposed to accommodate the non-cytotoxic nature of molecularly targeted agents. In particular, the use of alternative endpoints and controls has been suggested. The objectives of this survey are to review the designs of contemporary phase II trials, to compare trials of cytotoxic versus non-cytotoxic regimens, and to identify predictors of acceptance for presentation. Methods: Abstracts of phase II trials of systemic anticancer therapy published in the 2005 ASCO Proceedings were hand searched. The trial context, type of intervention, trial

APA, Harvard, Vancouver, ISO, and other styles

44

Sozu, Takashi, Tomoyuki Sugimoto, and Toshimitsu Hamasaki. "Statistical Issues in Clinical Trials with Multiple Primary Endpoints." Japanese Journal of Biometrics 34, no. 1 (2013): 35–52. http://dx.doi.org/10.5691/jjb.34.35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Tang, Dei-In, Clare Gnecco, and Nancy L. Geller. "Design of Group Sequential Clinical Trials with Multiple Endpoints." Journal of the American Statistical Association 84, no. 407 (1989): 776. http://dx.doi.org/10.2307/2289665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Bloch, Daniel A., Tze Leung Lai, and Pascale Tubert-Bitter. "One-Sided Tests in Clinical Trials with Multiple Endpoints." Biometrics 57, no. 4 (2001): 1039–47. http://dx.doi.org/10.1111/j.0006-341x.2001.01039.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Perlman, Michael D., and Lang Wu. "A Note on One‐Sided Tests with Multiple Endpoints." Biometrics 60, no. 1 (2004): 276–80. http://dx.doi.org/10.1111/j.0006-341x.2004.00159.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Tang, Dei-In, Clare Gnecco, and Nancy L. Geller. "Design of Group Sequential Clinical Trials with Multiple Endpoints." Journal of the American Statistical Association 84, no. 407 (1989): 775–79. http://dx.doi.org/10.1080/01621459.1989.10478836.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Sun, Anna, Xiaoyu Dong, and Yi Tsong. "Sample Size Determination for Equivalence Assessment with Multiple Endpoints." Journal of Biopharmaceutical Statistics 24, no. 6 (2014): 1203–14. http://dx.doi.org/10.1080/10543406.2014.941986.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Neuhäuser, Markus. "How to deal with multiple endpoints in clinical trials." Fundamental and Clinical Pharmacology 20, no. 6 (2006): 515–23. http://dx.doi.org/10.1111/j.1472-8206.2006.00437.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!